

Review of: "Tocilizumab Plus Corticosteroid in Elderly Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Cohort Study"

Michael Frass

Potential competing interests: No potential competing interests to declare.

This is an interesting study that should be published. However, the abstract should also mention the limitations. A major limitation is the lack of decision making regarding tocilizumab administration.

Further comments:

Conclusion and Relevance. "There was no difference in the incidence of mechanical ventilation by day 28 between the patients who were on tocilizumab and those who were not.": In Results it says, $p < 0.016$. Please clarify this contradiction.

Data Source: For drugs throughout the manuscript please include brand name, company, town, country.

Statistical Analysis: "In April 2019, the American Statistical Association (ASA) formally and strongly advocated abandoning the following terms, "statistical significance", "significantly different," " $p < 0.05$," and "nonsignificant"." Please provide reference.

Study Design: "Tocilizumab was administered as a single fixed dose of 400 mg along with either methylprednisolone or dexamethasone.": On which basis was it decided to add Tocilizumab?